Introduction
============

Coronary microembolization (CME) is a critical and frequent clinical complication, usually induced by spontaneous rupture of atherosclerotic plaque in acute coronary syndrome or iatrogenic rupture during percutaneous coronary intervention ([@B19], [@B17]; [@B32]). CME captures increasing attention due to the undesirable consequences, such as regional myocardial contractile dysfunction and malignant arrhythmias ([@B11]). CME patients are also associated with poor clinical outcomes ([@B16]; [@B14]).

It is known that several pathophysiological processes are involved in CME. Leukocyte infiltration is one of the core features in the occurrence of microinfarcts caused by CME, so inflammatory response might be responsible for the contractile dysfunction following CME ([@B9]). It is worth mentioning that tumor necrosis factor-α (TNF-α) could also play a causal role in CME-related contractile dysfunction ([@B18]), and most likely through triggering cardiomyocyte apoptosis and sphingosine production ([@B36]; [@B6]). Moreover, the oxidation of contractile proteins may contribute to the contractile impairment following CME ([@B4]). Till now, the specific molecular mechanisms related to CME remain largely elusive. Further understanding of the underlying mechanisms of CME might help to develop novel therapeutic strategies to alleviate the consequences of CME and improve outcomes of CME patients.

Modern approaches and methodologies of system biology analysis are becoming increasingly important in clarifying disease mechanisms. Novel proteomics techniques, liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) technology are powerful tools to detect protein changes and low-abundance protein alternations in injured tissue samples and experimental disease models. Isobaric tags for relative and absolute quantitation (iTRAQ), a MS-based proteomics approach, is helpful to compare protein expression levels between multiple samples, and can provide accurate mass measurement of critical changes in the amounts of proteins ([@B38]). Using proteomic methods, previous studies have uncovered several novel pathophysiological processes, potential therapeutic targets, or biomarkers in the context of myocardial infarction, cardiac remodeling, and dilated cardiomyopathy ([@B21]; [@B40]; [@B20]; [@B37]). However, there is only scanty in-depth analysis of the protein changes following CME.

In the present study, iTRAQ labeling combined with LC-MS/MS techniques were utilized to investigate the differentially expressed proteins and pathways in the cardiac tissues of CME mice.

Materials and Methods {#s1}
=====================

Animals
-------

Adult male C57BL/6 mice (8 weeks old, 22--25 g) were purchased from LingChang BioTech Co. Ltd. (Shanghai, China). Mice were randomly divided into the following two groups: sham-operation group (SO, *n* = 12) and CME group (CME, *n* = 12). The mouse CME model was established as described in our previous study ([@B5]). Briefly, mechanically ventilated mice were anesthetized with 1.5% isoflurane (Baxter International Inc., United States), and then thoracotomy was performed to expose the ascending aorta and heart. Simultaneous with the occlusion of the ascending aorta for 15 s, a total of 500,000 polyethylene microspheres (Dyno Particles AS, Norway) with an average diameter of 9 μm were injected into the left ventricle chamber. The SO group was injected with saline instead of microspheres. Then, after the measurement of cardiac function, all mice were sacrificed, and the hearts were quickly sampled and stored in liquid nitrogen for further analysis.

The investigation was approved by the Animal Care and Use Committee of Fudan University Zhongshan Hospital, and all protocols conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

Detection of Cardiac Function
-----------------------------

Three days after polyethylene microspheres or saline injection, transthoracic echocardiography was performed using Vevo770 ultrasound systems (VisualSonics, Canada) as previously described ([@B39]). The mice were anesthetized with 2% isoflurane (Baxter, Denmark) and laid supine on a heated platform. Left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and fractional shortening (FS) were measured and calculated from M-mode images.

Histological Analysis
---------------------

Tissues from the apical heart region were dissected, fixed in 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm sections. For morphological observations, the sections were stained with hematoxylin--eosin (HE) or Masson trichrome to detect cardiac morphology and collagen deposition, respectively. For immunohistochemical analyses, the paraffin sections were deparaffinized in xylene, rehydrated in ethanol, and soaked in 3% hydrogen peroxide to quench endogenous peroxidase activity. The sections were incubated with anti-F4/80 (Abcam, UK) at 4°C overnight. They were then rinsed in PBS and incubated with secondary antibody conjugated to HRP followed by a diaminobenzidine (DAB) substrate and counterstaining with hematoxylin. Histological images were obtained using an Olympus BX-51 light microscope (Olympus America Inc., United States) and measured using Image J software (Version 1.50, National Institutes of Health, United States).

Protein Preparation
-------------------

Two heart samples from each group were randomly selected for proteomics analysis. Each sample (50 mg) was homogenized in lysis buffer containing 1% protease inhibitor cocktail (Thermo Fisher Scientific, United States), and then ultra-sonicated to extract total proteins. The suspension was centrifuged at 14,000 *g* for 45 min at 4°C. Next, the supernatant was collected, and protein concentration was determined by bicinchoninic acid (BCA) assay method. Protein (200 μg) was reduced with 100 mM dithiothreitol (DTT) at 100°C for 5 min and subsequently alkylated with 50 mM iodoacetamide (IAA) for 30 min in darkness. All samples were digested with trypsin (Promega, United States) at 37°C for 16--18 h, reconstituted using 40 μl dissolution buffer, and then labeled with tags with an iTRAQ reagent kit (AB Sciex, United States) following the manufacturer's protocol.

LC-MS/MS Analysis
-----------------

Labeled samples were separated through online reversed-phase chromatography using Easy nLC1000 system (Thermo Fisher Scientific, United States). The peptides were autoloaded into a C18 trap column (2 cm × 100 μm, 5 μm; Thermo Fisher Scientific, United States), and subsequently eluted into a C18 analytical column (75 μm × 100 mm, 3 μm; Thermo Fisher Scientific, United States) for gradient elution at a flow rate of 250 nL/min for 120 min. LC-MS/MS was conducted using a Q-Exactive (Thermo Fisher Scientific, United States) mass spectrometer. The procedure was performed in positive ion mode with MS1 survey scan (m/z: 300--1800) at a resolution of 70,000, followed by 10 higher-energy collisional dissociation (HCD) type MS2 scans with a resolution of 17,500.

Protein Identification
----------------------

The MS raw files were processed using Proteome Discoverer 1.3 software (Thermo Fisher Scientific, United States). Database searching of the raw data was conducted with Mascot 2.2 against the UniProt mouse database which included 17,197 protein sequences. The following parameters were used in the Mascot search: two missed trypsin cleavage sites, carbamidomethyl fixed modification, methionine oxidation variable modifications, ±20 ppm peptide mass tolerance, 0.1 Da fragment mass tolerance and decoy database pattern. Peptides were identified and filtered to 1% false discovery rate (FDR).

Bioinformatics Analysis
-----------------------

Proteins were regarded as differentially expressed if they revealed more than 1.2-fold change (≥1.2 or ≤0.83) and the *P*-value was \<0.05 based on Student's *t*-test between the groups. Matrix2png program^[1](#fn01){ref-type="fn"}^ was used for making heatmap visualizations of differentially expressed proteins. The analysis of Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and protein--protein interaction (PPI) network was preceded using the online bioinformatics data analysis tool OmicsBean^[2](#fn02){ref-type="fn"}^.

Quantitative PCR
----------------

Total RNA was extracted from heart samples using TRIzol Reagent (Invitrogen Biotechnology, United States). cDNA was synthesized from 400 ng of total RNA using PrimeScript RT Master Mix (Takara Biomedical Technology, Japan). Quantitative PCR (qPCR) was performed using SYBR Premix Ex Taq (Takara Biomedical Technology, Japan) on a CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, United States) following the manufacturer's protocol. Succinate dehydrogenase (Sdha and Sdhb), Rho GDP dissociation inhibitor α (Arhgdia), and Filamin-A (Flna) were selected as target genes. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression was used as internal reference, and the relative level of target gene expression was calculated by the 2^-ΔΔCq^ method. The sequences of the specific primers for each gene were listed in **Table [1](#T1){ref-type="table"}**.

###### 

Primer sequences for quantitative PCR.

  Target Gene   Gene ID   Forward Sequence (5′ → 3′)   Reverse Sequence (5′ → 3′)
  ------------- --------- ---------------------------- ----------------------------
  Sdha          66945     GGAACACTCCAAAAA CAGACCT      CCACCACTGGGTAT TGAGTAGAA
  Sdhb          67680     AATTTGCCATTTACCG ATGGGA      AGCATCCAACACCA TAGGTCC
  Arhgdia       192662    AAGGACGATGAAA GCCTCCG        GGTCAGTCGAGTC ACAATGACA
  Flna          192176    GAGTTCGGCATTT GGACTAGG       GGGCTATCAGGTAT GTGCTCC
  Gapdh         14433     CGTGCCGCCTGGA GAAACC         TGGAAGAGTGGGAG TTGCTGTTG
                                                       

Western Blotting
----------------

Total protein (40 μg) was loaded onto a 8--12% sodium dodecyl sulfate--polyacrylamide gel, and then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, United States). The membranes were blocked in Tris-buffered saline +0.1% Tween-20 (TBST) containing 5% bovine serum albumin (BSA) for 1 h and then incubated with primary antibody against SDHA, SDHB, RhoGDIα, FLNA (Abcam, United Kingdom) and GAPDH (Cell Signaling Technology, United States) at 4°C overnight. GAPDH expression was used as internal control. The membranes were incubated with secondary antibody (Cell Signaling Technology, United States) for 1.5 h after three washes. The antigen--antibody complexes were detected using an enhanced chemiluminescence kit (Thermo Fisher Scientific, United States).

Statistical Analysis
--------------------

Continuous variables were analyzed for distribution status. Data with normal distribution were presented as mean ± SEM. Differences between groups were determined by Student's *t*-test. *P* values \<0.05 were considered statistically significant. All data analyses were performed using GraphPad Prism version 5.0 software (GraphPad Prism, United States).

Results
=======

CME-Induced Cardiac Contractile Dysfunction
-------------------------------------------

Echocardiography results demonstrated that cardiac systolic function was impaired as characterized by significant decreased LVEF and FS in the CME group as compared with the respective values in SO group (*P* \< 0.01) (**Figures [1A](#F1){ref-type="fig"}--[C](#F1){ref-type="fig"}**). In addition, LVEDD and LVEDS were significantly increased in CME mice (*P* \< 0.01) (**Figures [1D,E](#F1){ref-type="fig"}**).

![Cardiac function detection by echocardiography. **(A)** Representative M-mode echocardiograms. Group data for **(B)** left ventricular ejection fraction (LVEF), **(C)** fractional shortening (FS), **(D)** left ventricular end-diastolic diameter (LVEDD), and **(E)** left ventricular end-systolic diameter (LVEDS). ^∗∗^*P* \< 0.01; *n* = 12 per group.](fphys-09-01318-g001){#F1}

CME-Induced Cardiac Morphological Changes
-----------------------------------------

HE staining revealed disorganized myocytes around the microspheres deposited in coronary microcirculation of hearts in the CME group (**Figure [2A](#F2){ref-type="fig"}**). Notably, hearts of CME mice exhibited considerably higher amounts of collagen, especially around the microspheres, as compared with hearts from the SO group (**Figures [2B,C](#F2){ref-type="fig"}**). CME also resulted in enhanced inflammatory cells infiltrating in the myocardium, primarily localizing around the microspheres, as demonstrated by the accumulation of enriched F4/80^+^ macrophages in the CME hearts (**Figures [2D,E](#F2){ref-type="fig"}**).

![Histological analysis of the hearts from three groups. **(A)** Representative HE-staining micrographs to visualize myocytes arrangement. **(B)** Cardiac sections were stained with Masson to visualize collagen deposition around the microspheres. **(C)** The quantitative analysis of collagen contents (%). **(D)** Immunohistochemical staining of F4/80 to reflect macrophage infiltration. **(E)** Integrated optical density (IOD) of F4/80 in cardiac tissues. *n* = 6 per group. Scale bars = 50 μm. Black arrows indicated the microspheres. ^∗∗^*P* \< 0.01.](fphys-09-01318-g002){#F2}

Proteomics Analysis
-------------------

A total of 1145 mouse proteins were unambiguously identified in this proteomics analysis. Comparison between the two groups revealed that 84 proteins were upregulated and 165 downregulated in the CME group compared with the SO group (**Figure [3A](#F3){ref-type="fig"}**). Then, by using heatmap, the expression levels of these 249 differentially expressed proteins were elaborately and visually displayed (**Figure [3B](#F3){ref-type="fig"}**).

![Proteomics analysis of the differentially expressed proteins. **(A)** Numbers of upregulated and downregulated proteins in CME mice. **(B)** Heatmap of the expression levels of the 249 differentially expressed proteins, red and green reflected high and low expression levels, respectively.](fphys-09-01318-g003){#F3}

GO Enrichment and Pathway Analysis
----------------------------------

GO enrichment analysis was conducted on the 249 differentially expressed proteins to further explore their biological functions. The top 15 significantly enriched GO terms were depicted in **Figure [4A](#F4){ref-type="fig"}**. In biological process analysis, fibril organization was the most striking term, followed by other cytoskeleton or metabolism related processes, for instance, cytoskeleton organization, cellular respiration, oxidation--reduction process, response to oxygen-containing compound, and electron transport chain. Concerning cell component, most of these annotated proteins were localized in organelles or membrane-bounded organelles. Molecular function analysis revealed that protein binding (cell adhesion molecule binding, cadherin binding, and protein complex binding) and metabolic enzymes activity (electron carrier activity, disulfide oxidoreductase activity, and phosphatidylcholine-sterol O-acyltransferase activator activity) were the predominant terms (**Figure [4A](#F4){ref-type="fig"}**). Top 15 KEGG pathways were listed in **Figure [4B](#F4){ref-type="fig"}**, metabolism pathways, including citrate cycle, oxidative phosphorylation, and carbon metabolism, were significantly enriched (**Figures [4B,C](#F4){ref-type="fig"}**). In addition, peroxisome proliferator-activated receptor (PPAR) signaling pathway, which transcriptionally regulates myocardial energy metabolism ([@B13]), was found to be tangled following CME.

![GO enrichment and pathway analysis of the 249 differentially expressed proteins. **(A)** Bar chart depicting the GO classification of the differentially expressed proteins in terms of biological process, cellular component, and molecular function. **(B)** Top 15 KEGG pathways enriched by the differentially expressed proteins. **(C)** Classification of the enriched KEGG pathways.](fphys-09-01318-g004){#F4}

PPI Analysis
------------

We then focused on metabolism pathways and cytoskeleton organization changes based on the enriched GO terms or pathways. PPI analysis using OmicsBean online tool provided us distinct networks formed by interacting proteins with visual displayed data to get insight into the pathogenesis involved in CME. Three metabolism pathways (carbon metabolism, oxidative phosphorylation, and citrate cycle) refined by KEGG metabolism classification, were enrolled for PPI analysis (**Figure [5A](#F5){ref-type="fig"}**). Cytoskeleton organization process related proteins were shown in **Figure [5B](#F5){ref-type="fig"}**.

![PPI networks. **(A)** PPI analysis of the metabolism related pathways, including carbon metabolism, oxidative phosphorylation, and citrate cycle **(B)** PPI analysis of the cytoskeleton organization process.](fphys-09-01318-g005){#F5}

Quantitative PCR and Western Blotting Validation
------------------------------------------------

To verify the proteomics results and to validate the altered myocardial energy metabolism and cytoskeleton organization following CME, we first limited the target proteins in energy metabolism and cytoskeleton organization processes (PPI analysis in **Figure [5](#F5){ref-type="fig"}**). To further narrow the scope of the target proteins, we scanned literatures about the proteins listed in the PPI analysis, and selected the proteins which have a direct and particularly close connection to energy metabolism and cytoskeleton organization for validation. Ultimately, two enzymes involved in the citrate cycle, SDHA and SDHB, and two proteins participated in cytoskeleton organization, RhoGDIα and FLNA, were enrolled for qPCR and Western blotting analysis. In the transcriptional level, we observed a remarkable upregulation of SDHA and SDHB, and downregulation of RhoGDIα and FLNA mRNA expression in the CME group (**Figure [6A](#F6){ref-type="fig"}**). The protein expression levels of SDHA and SDHB were also significantly increased, RhoGDIα and FLNA decreased in the CME group as compared with the SO group (**Figures [6B,C](#F6){ref-type="fig"}**), which were all consistent with the proteomics results.

![Validation of the proteomics results by qPCR and Western blotting. **(A)** Results of qPCR for the mRNA levels of SDHA, SDHB, RhoGDIα, and FLNA. **(B)** Results of Western blotting for SDHA, SDHB, RhoGDIα, and FLNA. **(C)** Densitometric analysis of relative protein expressions, GAPDH was used as internal control. *n* = 4 per group. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](fphys-09-01318-g006){#F6}

Discussion
==========

Cardiac contractile dysfunction, myocardial fibrosis, and enhanced inflammation were evidenced in this mice model of CME. To further understand the pathophysiological processes of CME, the differential protein expression pattern was displayed between the sham-operated and CME mice using iTRAQ and LC-MS/MS based proteomics technology, and then verified by qPCR and Western blotting analysis. A total of 249 proteins were revealed to be differentially expressed following CME. GO enrichment and KEGG pathway analysis suggested that several cytoskeleton or metabolism related processes, such as fibril organization, carbon metabolism, and citrate cycle, were perturbed in CME mice. The extensive proteomics analysis allowed for the first time an in-depth observation of the protein alterations in CME.

It is well known that heart exhibits a high capacity of adenosine 5′-triphosphate (ATP) production, which is indispensable for continuous mechanical contraction ([@B33]). Perturbations in ATP production resulting from energy metabolism disturbances might impair the cardiac contractile function. The term "metabolic remodeling" in cardiac hypertrophy and heart failure has been well established and may provide certain guidance for new therapeutic directions ([@B27]; [@B1]). It is noteworthy that previous studies on CME have largely focused on myocardial apoptosis or cardiac inflammation ([@B10]; [@B31]; [@B6]), while energy metabolism disturbances in case of CME have received little deliberate attention. Present proteomics analysis depicted several energy metabolic abnormalities in CME mice, especially citrate cycle, a key pathway involved in the oxidation of glucose, fatty acids, and amino acid metabolism, was found to be dysregulated. Besides, the metabolism upstream modulator, PPAR signaling pathway, was also enriched as detected by the KEGG pathway analysis in CME mice. PPAR-targeted drugs have been demonstrated to confer cardioprotection in cardiovascular diseases ([@B30]; [@B3]), it is therefore possible that these drugs might also serve as a feasible strategy in the treatment of CME. Meanwhile, KEGG pathway analysis implied cardiac muscle contraction impairment in CME mice, indicating that the cardiac dysfunction following CME may be at least partly explained by the impaired ATP production due to energy metabolic abnormalities.

In addition, PPI analysis revealed that two subunits of succinate dehydrogenase, SDHA and SDHB, were the altered proteins, which were known to be involved in the citrate cycle. Succinate is not only a metabolic intermediate during citrate cycle but also involves in the mitochondrial reactive oxygen species (ROS) production process via reverse electron transport (RET) and thereby enhances the inflammatory responses ([@B34]; [@B8]). Previous study has shown that SDH is responsible for the accumulation and oxidation of succinate during cardiac ischemia/reperfusion (I/R). Inhibiting SDH could reduce ROS production and protect against I/R injury ([@B8]). Heatmap analysis, qPCR and Western blotting analysis revealed an increased expression level of SDHA and SDHB following CME in the present study, which might be a source of ROS production in CME mice. Not surprisingly, KEGG pathway analysis also demonstrated abnormal oxidative phosphorylation in CME mice, in line with the alteration of oxidation--reduction biological process by GO analysis. Previous studies showed that ROS accumulation could lead to oxidative modification of tropomyosin ([@B4]). Moreover, ROS generation may amplify inflammatory responses via distinct molecular pathways ([@B25]), both redox signaling and inflammation could enhance cardiac fibrosis by inducing the proliferation and differentiation of fibroblasts and the deposition of collagen ([@B29]). In line with the proteomics results, pathological analysis demonstrated increased inflammation and collagen deposition in this CME mice model. It is to note that above changes hinting mitochondrial dysfunction were also the common disease features of various neurodegenerative disorders including Alzheimer's, Parkinson's, and Huntington's diseases ([@B35]; [@B22]; [@B28]). Thus, our results also indicated the close association of cardiac and neuroembolism-related diseases, showing ischemic cardiac and neurological diseases share the common pathogenesis including enhanced oxidative stress and mitochondrial dysfunction.

The proteomics analysis used in the present study revealed Arhgdia-encoded protein RhoGDIα was decreased in CME mice, this finding was further confirmed by Western blotting and qPCR analysis. It is known that the ubiquitously expressed protein RhoGDIα interacts with several Rho GTPases and maintains them in an inactive state by inhibiting the dissociation of GDP from them ([@B2]). Rho family proteins could regulate several pathways including actin organization, apoptosis, proliferation, migration, and transformation. RhoGDIα thus serves as a pleiotropic modulator ([@B7]; [@B26]). Previous study reported that RhoGDIα might exert influence on cardiac electrical activity via regulating expression and/or activity of cardiac structural proteins, such as connexin 40 ([@B23]), and this might be linked with the pathogenesis of various malignant arrhythmias following CME ([@B15]). Another cytoskeleton-related protein FLNA was also found to be downregulated following CME in the present study. Previous studies demonstrating that FLNA was essential for actin cytoskeleton remodeling and intercellular junctions during heart development ([@B12]; [@B24]), our finding hinted a possible role of FLNA in post-CME remodeling.

Admittedly, some limitations of this study need to be acknowledged. First, quantitative proteomics alone is not enough to unearth the metabolic changes comprehensively, because it can only discover the expression changes of metabolic enzymes in protein level. However, the alterations of enzyme activities are also important for metabolism. Thus, proteomics along with kinomics or metabolomics are necessary for exploring the more detailed metabolic alterations following CME. Second, all the analyses were made on tissue samples obtained at 3 days after CME, future studies are warranted to clarify the long-term metabolic changes or remodeling-induced changes in this CME model. Third, although we have validated the expression changes of four proteins in this study, further functional experiments are warranted to evaluate the detailed roles of these differentially expressed proteins. Last but not least, although the mice model is a powerful tool to uncover pathogenesis of human diseases, the differences in gene expression patterns between them should be taken into account, further investigations in human cardiac tissues with coronary microembolism are needed to clarify the disease pathogenesis.

Conclusion
==========

Using a mice model of CME and state-of-the-art iTRAQ labeling and LC-MS/MS technology, we provide the first proteomic characterization of myocardial tissues of CME mice. Bioinformatics analysis indicates significant alternations of the cytoskeleton and metabolism-related proteins following CME, future studies are warranted to verify if strategies targeting these differentially expressed molecular proteins and signaling pathways might confer novel therapeutic options for CME or not.
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